50 results
8-K
EX-99.1
CRVS
Corvus Pharmaceuticals Inc
6 May 24
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
4:01pm
scan or by Modified Severity-Weighted Assessment Tool (mSWAT) for patients with cutaneous involvement. PTCL-NOS, peripheral T cell lymphoma
8-K
EX-99.1
CRVS
Corvus Pharmaceuticals Inc
19 Mar 24
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
4:02pm
(eligible patient population), as of January 22, 2024, that were measurable by CT scan or by Modified Severity-Weighted Assessment Tool (mSWAT) for patients
8-K
EX-99.1
q0dx2hz w4p7ldc
10 Mar 22
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
4:06pm